248 related articles for article (PubMed ID: 18403492)
21. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme.
Baumann F; Bjeljac M; Kollias SS; Baumert BG; Brandner S; Rousson V; Yonekawa Y; Bernays RL
J Neurooncol; 2004; 67(1-2):191-200. PubMed ID: 15072467
[TBL] [Abstract][Full Text] [Related]
22. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
[TBL] [Abstract][Full Text] [Related]
23. A prospective study of temozolomide plus thalidomide during and after radiation therapy for pediatric diffuse pontine gliomas: preliminary results of the Korean Society for Pediatric Neuro-Oncology study.
Kim CY; Kim SK; Phi JH; Lee MM; Kim IA; Kim IH; Wang KC; Jung HL; Lee MJ; Cho BK
J Neurooncol; 2010 Nov; 100(2):193-8. PubMed ID: 20309719
[TBL] [Abstract][Full Text] [Related]
24. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
[TBL] [Abstract][Full Text] [Related]
25. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.
Lee EQ; Kaley TJ; Duda DG; Schiff D; Lassman AB; Wong ET; Mikkelsen T; Purow BW; Muzikansky A; Ancukiewicz M; Huse JT; Ramkissoon S; Drappatz J; Norden AD; Beroukhim R; Weiss SE; Alexander BM; McCluskey CS; Gerard M; Smith KH; Jain RK; Batchelor TT; Ligon KL; Wen PY
Clin Cancer Res; 2015 Aug; 21(16):3610-8. PubMed ID: 25910950
[TBL] [Abstract][Full Text] [Related]
26. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Reardon DA; Vredenburgh JJ; Desjardins A; Peters K; Gururangan S; Sampson JH; Marcello J; Herndon JE; McLendon RE; Janney D; Friedman AH; Bigner DD; Friedman HS
J Neurooncol; 2011 Jan; 101(1):57-66. PubMed ID: 20443129
[TBL] [Abstract][Full Text] [Related]
27. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Prados MD; Yung WK; Fine HA; Greenberg HS; Junck L; Chang SM; Nicholas MK; Robins HI; Mehta MP; Fink KL; Jaeckle KA; Kuhn J; Hess KR; Schold SC;
Neuro Oncol; 2004 Jan; 6(1):33-7. PubMed ID: 14769138
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme.
Chang SM; Lamborn KR; Malec M; Larson D; Wara W; Sneed P; Rabbitt J; Page M; Nicholas MK; Prados MD
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):353-7. PubMed ID: 15380566
[TBL] [Abstract][Full Text] [Related]
29. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Kesari S; Schiff D; Drappatz J; LaFrankie D; Doherty L; Macklin EA; Muzikansky A; Santagata S; Ligon KL; Norden AD; Ciampa A; Bradshaw J; Levy B; Radakovic G; Ramakrishna N; Black PM; Wen PY
Clin Cancer Res; 2009 Jan; 15(1):330-7. PubMed ID: 19118062
[TBL] [Abstract][Full Text] [Related]
31. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
Hainsworth JD; Ervin T; Friedman E; Priego V; Murphy PB; Clark BL; Lamar RE
Cancer; 2010 Aug; 116(15):3663-9. PubMed ID: 20564147
[TBL] [Abstract][Full Text] [Related]
32. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
[TBL] [Abstract][Full Text] [Related]
34. Temozolomide and thalidomide in the treatment of glioblastoma multiforme.
Riva M; Imbesi F; Beghi E; Galli C; Citterio A; Trapani P; Sterzi R; Collice M
Anticancer Res; 2007; 27(2):1067-71. PubMed ID: 17465245
[TBL] [Abstract][Full Text] [Related]
35. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
[TBL] [Abstract][Full Text] [Related]
37. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Chinot OL; Wick W; Mason W; Henriksson R; Saran F; Nishikawa R; Carpentier AF; Hoang-Xuan K; Kavan P; Cernea D; Brandes AA; Hilton M; Abrey L; Cloughesy T
N Engl J Med; 2014 Feb; 370(8):709-22. PubMed ID: 24552318
[TBL] [Abstract][Full Text] [Related]
38. MGMT gene silencing and benefit from temozolomide in glioblastoma.
Hegi ME; Diserens AC; Gorlia T; Hamou MF; de Tribolet N; Weller M; Kros JM; Hainfellner JA; Mason W; Mariani L; Bromberg JE; Hau P; Mirimanoff RO; Cairncross JG; Janzer RC; Stupp R
N Engl J Med; 2005 Mar; 352(10):997-1003. PubMed ID: 15758010
[TBL] [Abstract][Full Text] [Related]
39. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.
Omuro A; Beal K; Gutin P; Karimi S; Correa DD; Kaley TJ; DeAngelis LM; Chan TA; Gavrilovic IT; Nolan C; Hormigo A; Lassman AB; Mellinghoff I; Grommes C; Reiner AS; Panageas KS; Baser RE; Tabar V; Pentsova E; Sanchez J; Barradas-Panchal R; Zhang J; Faivre G; Brennan CW; Abrey LE; Huse JT
Clin Cancer Res; 2014 Oct; 20(19):5023-31. PubMed ID: 25107913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
